How effective is sapropterin in keeping symptoms at bay?

How does sapropterin reduce symptoms in PKU patients?

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), the natural cofactor needed for phenylalanine hydroxylase to convert phenylalanine into tyrosine. In patients with residual enzyme activity, sapropterin enhances this pathway, lowering blood phenylalanine levels and thereby preventing or reversing neurocognitive symptoms tied to hyperphenylalaninemia. It works only in patients responsive to the BH4 challenge test.

Can sapropterin replace dietary phenylalanine restriction?

Sapropterin does not fully replace the low-phenylalanine diet. Many patients still require strict dietary control, sapropterin simply allows relaxed dietary restrictions and improved quality of life. Studies show 20-50% of patients achieve at least a 20-30% drop in blood phenylalanine after treatment.

What clinical data support its effectiveness?

Clinical trials demonstrate that sapropterin responders maintain blood phenylalanine levels within target ranges (120-360 µmol/L) with fewer dietary restrictions. Long-term extension studies confirm sustained control over 3-5 years, but non-responders show no benefit. Data from registries indicate that 30-70% of patients with milder mutations respond to sapropterin.

When does the patent for sapropterin expire?

The primary U.S. compound patent expired in 2015. Subsequent formulation and use patents held by BioMarin protect Kuvan until at least 2025. Biosimilars and generic versions may enter the market after 2025, but regulatory hurdles for small-molecule generics require bioequivalence demonstration.